Thioridazine has been known as an antipsychotic agent, but it also has anticancer activity. However, the effect of thioridazine on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitization has not yet been studied. Here, we investigated the ability of thioridazine to sensitize TRAIL-mediated apoptosis. Combined treatment with thioridazine and TRAIL markedly induced apoptosis in various human carcinoma cells, including renal carcinoma (Caki, ACHN, and A498), breast carcinoma (MDA-MB231), and glioma (U251MG) cells, but not in normal mouse kidney cells (TMCK-1) and human normal mesangial cells. We found that thioridazine downregulated c-FLIP(L) and Mcl-1 expression at the post-translational level via an increase in proteasome activity. The overexpression of c-FLIP(L) and Mcl-1 overcame thioridazine plus TRAIL-induced apoptosis. We further observed that thioridazine inhibited the Akt signaling pathway. In contrast, although other phosphatidylinositol-3-kinase/Akt inhibitors (LY294002 and wortmannin) sensitized TRAIL-mediated apoptosis, c-FLIP(L) and Mcl-1 expressions were not altered. Thioridazine (10-[2-(1-methyl-2-piperidyl) ethyl]-2-(methylthio) phenothiazine) is a first-generation antipsychotic drug that has been used to treat psychotic disorders, such as psychosis and schizophrenia.
Thioridazine (10-[2-(1-methyl-2-piperidyl) ethyl]-2-(methylthio) phenothiazine) is a first-generation antipsychotic drug that has been used to treat psychotic disorders, such as psychosis and schizophrenia. 1, 2 Thioridazine also has antimicrobial activity and is thus used as a treatment against drug-resistant organisms, such as Mycobacterium tuberculosis. 3, 4 In addition, thioridazine has anticancer effects, including antiproliferative and antisurvival effects. For example, thioridazine increased apoptosis in cervical and endometrial cancer, 5 ovarian cancer, 6 activated B-cell subtype of diffuse B-cell lymphoma, 7 neuroblastoma and glioma, 8 leukemia, 9 and melanoma cells. 10 One of the molecular mechanisms underlying the anticancer effects of thioridazine might be associated with the inhibition of the phosphatidylinositol-3-kinase (PI3K)/ Akt signaling pathway. 5, 6 The inhibition of mammalian target of rapamycin signaling is also one of the candidate mechanisms of thioridazine. 6 The inhibition of mitochondrial DNA polymerase and ATP production is involved in the thioridazine-induced apoptosis of leukemic cells. 9 However, the mechanism that underlies thioridazine-induced apoptosis has not been well documented. Because high concentrations of thioridazine cause side effects, such as dysrhythmia and sudden death, 11, 12 combined treatment with low concentrations of thioridazine plus other anticancer drugs may reduce the occurrence of side effects and improve the drug's anticancer effects.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) activates the extrinsic apoptotic pathway. TRAIL binds to death receptors (DRs; DR4 and DR5) and then recruits caspase-8 into a death-inducing signaling complex (DISC). The activation of caspase-8 directly activates caspase-3 or induces mitochondria-mediated caspase-3 activation, which results in apoptosis. Previous studies have shown that cancer cells highly express DRs, whereas normal cells highly express the decoy receptors. 13 Moreover, the level of cellular FLICE-inhibiting protein (c-FLIP(L)), which inhibits caspase-8 recruitment to DISC, is higher in normal cells than in tumor cells.
14 Accordingly, TRAIL had been known as a promising anticancer drug. 15 However, many cancer cells represent resistance to TRAIL-mediated apoptosis via multiple mechanisms. The downregulation of DRs and/or upregulation of antiapoptotic proteins (c-FLIP(L), the Bcl-2 family proteins (Bcl-2, Bcl-xL, and Mcl-1) and the inhibitor of apoptosis proteins (IAPs)) have been demonstrated to be associated with TRAIL resistance. [16] [17] [18] [19] [20] Previous studies have shown that TRAILresistant cancer cells can be sensitized by combination treatment. Thus, the development of TRAIL sensitizers is needed to increase sensitivity against TRAIL.
In the present study, we assessed the sensitizing effects of thioridazine on TRAIL-induced apoptosis in human renal carcinoma Caki cells. Combination treatment with TRAIL and thioridazine could facilitate the development of an effective strategy for cancer treatment.
Results
Thioridazine sensitizes to TRAIL-mediated apoptosis in human renal carcinoma, breast carcinoma, and glioma cells, but not normal cells. Thioridazine has anticancer effects on multiple cancer cells. [5] [6] [7] [8] [9] [10] Therefore, we investigated the ability of thioridazine to sensitize human renal carcinoma Caki cells to TRAIL. To determine whether thioridazine plus TRAIL induce apoptosis, an FACS analysis to measure the DNA content and western blotting to detect the cleavage of PARP, a substrate of caspase-3, were performed. Thioridazine or TRAIL did not affect apoptosis, but a combined treatment with thioridazine plus TRAIL markedly increased the sub-G1 population and PARP cleavage ( Figure 1a ). In addition, thioridazine plus TRAIL induced chromatin damage in the nuclei (Figure 1b ) and cytoplasmic histone-associated DNA fragments (Figure 1c ). Combined treatment with thioridazine and TRAIL increased caspase-3 activation (Figure 1d) , and z-VAD-fmk (z-VAD), a pan-caspase inhibitor, markedly inhibited thioridazine plus TRAIL-induced apoptosis (Figure 1e, upper panel) . The cleavage of PARP and caspase-3 was also blocked by z-VAD treatment (Figure 1e , lower panel). To identify the mechanisms underlying sensitization to TRAIL by thioridazine, we examined the expression levels of apoptosis-related proteins, including the Bcl-2 family, IAP family, constituents of DISC (FADD and cellular FLICE-inhibitory protein (c-FLIP(L)), and DRs in thioridazine-treated Caki cells. Thioridazine markedly downregulated c-FLIP(L) and Mcl-1 expression, but the expression of other proteins remained unchanged (Figure 1f ). These results indicate that thioridazine sensitizes Caki cells to TRAIL-mediated apoptosis.
Next, we used other human renal carcinoma (ACHN and A498), human breast carcinoma (MDA-MB231), and human glioma (U251MG) cells to investigate the anticancer effect of thioridazine on other carcinoma cells. As shown in Figure 2a , combined treatment with thioridazine plus TRAIL induced apoptosis and PARP cleavage in ACHN, A498, MDA-MB231, and U251MG cells. In contrast, thioridazine plus TRAIL induced neither cellular shrinkage nor apoptosis in normal cells (mouse kidney cells (TMCK-1) and human mesangial cells), whereas cellular shrinkage and blebbing was detected in Caki cells (Figure 2b) . Furthermore, thioridazine induced the downregulation of c-FLIP(L) and Mcl-1 expression in carcinoma cells, but not in normal cells (Figure 2c ). These data indicate that thioridazine can sensitize cancer cells other than Caki cells to TRAIL. Previous studies reported that c-FLIP(L) and Mcl-1 are degraded by the proteasome-ubiquitin system. 21, 22 Therefore, we investigated whether the downregulation of c-FLIP(L) and Mcl-1 is associated with proteasome activity. First, we examined the ability of proteasome inhibitors (MG132 and lactacystin) to reverse the thioridazine-mediated downregulation of c-FLIP(L) and Mcl-1 expression. As shown in Figure 4a , proteasome inhibitors blocked the downregulation of c-FLIP(L) and Mcl-1 expression. Next, we measured the chymotrypsin-like activity of proteasome with Suc-Leu-LeuVal-Tyr-AMC as the proteasome substrate to investigate the ability of thioridazine to increase proteasome activity.
As expected, thioridazine increased the chymotrypsin-like activity of the proteasome within 12 h (Figure 4b ). We used the proteasome sensor vector, ZsProSensor-1, to confirm the induction of proteasome activity by thioridazine. The vector encodes a destabilized green fluorescence protein (ZsGreen), which is rapidly degraded by proteasomes. For example, when proteasomes are inhibited, the fluorescent protein accumulates, which allows green fluorescence to be detected by fluorescence microscopy. Importantly, thioridazine decreased green fluorescence, whereas MG132 increased green fluorescence (Figure 4c ). We further examined the ability of thioridazine to modulate the protein expression of two critical proteasome subunits: 20S proteasome subunit alpha type 5 (PSMA5) and 19S proteasome non-ATPase regulatory subunit 4 (PSMD4/S5a). 23 However, the increase in the proteasome activity was not associated with PSMA5 and PSMD4/S5a expression in thioridazinetreated Caki cells. Next, we investigated the importance of the downregulation of c-FLIP(L) and Mcl-1 due to proteasome activation to thioridazine plus TRAIL-mediated apoptosis. When proteasome inhibitors (MG132 and lactacystin) reversed the downregulation of c-FLIP(L) and Mcl-1, the sub-G1 population and PARP cleavage were markedly inhibited in thioridazine plus TRAIL-treated cells (Figure 4e ). These data suggest that the downregulation of c-FLIP(L) and Mcl-1 expression due to the induction of proteasome activity is critical in thioridazine plus TRAIL-mediated apoptosis.
Inhibition of Akt signaling is involved in thioridazinemediated TRAIL sensitization. Thioridazine has been known to exert anticancer effects via the inhibition of the PI3K/Akt signaling pathways. 5, 6 To examine the involvement of the PI3K/Akt pathway in thioridazine-mediated TRAIL sensitization, we tested the effect of PI3K/Akt inhibitors (LY294002 and wortmannin) on c-FLIP(L) and Mcl-1 expression. Although LY294002 and wortmannin, similar to (Figure 5a ). The present study demonstrates that thioridazine, unlike LY294002 and wortmannin, exhibits an additional activity in downregulating c-FLIP(L) and Mcl-1 expression beyond the inhibition of Akt signaling. Therefore, we hypothesized that thioridazine could be a stronger TRAIL sensitizer than LY294002 and wortmannin. Our data indicated that the increased sensitivity to TRAIL-mediated apoptosis was most pronounced in thioridazine-treated cells (Figure 5b ). These data collectively suggest that thioridazine, via the downregulation of c-FLIP(L) and Mcl-1 expression, could serve as a more effective agent to induce TRAIL-mediated apoptosis.
Thioridazine increased ROS production. The effect of thioridazine on reactive oxygen species (ROS) production is controversial. Thioridazine increased the levels of ROS in myelin and mitochondria in rats, 24 but also had antioxidant activity via an interaction with the inner membrane of mitochondria in rat liver mitochondria. 25 We examined the ability of thioridazine to increase ROS production in Caki cells. As shown in Figures 6a and b , thioridazine markedly induced intracellular ROS production, and pretreatment with ROS scavengers (N-acetyl-L-cysteine (NAC), glutathione ethyl ester (GEE), and trolox) inhibited the increase in the sub-G1 population and PARP cleavage in thioridazine plus TRAIL-treated cells. Furthermore, all ROS scavengers reversed the downregulation of c-FLIP(L) and Mcl-1 and prevented the inhibition of Akt phosphorylation in thioridazine plus TRAIL-mediated cells. As shown in Figures 3 and 4 , both c-FLIP(L) and Mcl-1 expression were downregulated at the post-translational levels via a proteasome degradation pathway. Therefore, Caki cells were pretreated with ROS scavengers followed by the addition of thioridazine to further examine the association between ROS and the induction of 
Discussion
In this study, we demonstrated the mechanism that underlies the sensitization to TRAIL-mediated apoptosis due to thioridazine. Thioridazine induced the downregulation of c-FLIP(L) and Mcl-1 expressions at the post-translational levels via the upregulation of proteasome activity and decreased Akt phosphorylation. In addition, thioridazine increased intracellular ROS production, which is associated with the induction of proteasome activity and inhibition of Akt signaling. Therefore, our results suggest that thioridazine increased TRAIL-mediated apoptosis via the ROS-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L) (Figure 6d ). These findings support that thioridazine could be an attractive drug for TRAIL sensitization.
Thioridazine is well known to exert anticancer effects via the inhibition of the PI3K/Akt singling pathway. 5, 6 Previous studies reported that PI3K/Akt activation protected human leukemia HL60 cells from TRAIL-mediated apoptosis, 26 and the inhibition of PI3K/Akt augmented TRAIL sensitization in human leukemia, 27 neuroblastoma, 28 and colon cancer cells. 29 In our study, thioridazine also inhibited Akt phosphorylation (Figure 5a ). Previous studies reported that the PI3K/Akt signaling pathway is associated with c-FLIP(L) and Mcl-1 expression in murine B lymphocytes and ovarian cancer cells, respectively. 30, 31 In addition, PI3K/Akt modulates c-FLIP(L) and Mcl-1 protein stability. Moumen et al. 32 reported that PI3K/Akt maintains c-FLIP(L) protein stability via Met signaling in hepatocytes, and granulocyte-macrophage colony-stimulating factor enhances Mcl-1 stability via the activation of PI3K/Akt in neutrophils. 33 However, other PI3K/ Akt inhibitors (LY294002 and wortmannin) did not affect or downregulate c-FLIP(L) and Mcl-1 expression (Figure 5a ) or the induction of proteasome activity (data not shown). The thioridazine-mediated downregulation of c-FLIP(L) and Mcl-1 expression is probably independent of PI3K/Akt signaling in human renal carcinoma Caki cells ( Figure 5 ). Thus, thioridazine likely acts as a stronger sensitizer than LY294002 and wortmannin (Figure 5b) .
ROS are important signaling molecules that modulate cellular responses. Thioridazine markedly increased ROS production (Figure 6a) , and ROS was associated with thioridazine plus TRAIL-mediated apoptosis (Figure 6b) . Furthermore, we detected that ROS modulated the downregulation of c-FLIP(L) and Mcl-1 expression (Figure 6b ). According to previous reports, ROS have dual positive and negative functions on proteasome activity. In neutrophils and hepatocytes, ROS inhibited proteasome activity. 34, 35 In contrast, ROS increased proteasome activity in skeletal muscle myotubes and lens epithelial cells. 36, 37 In our study, the induction of proteasome activity by thioridazine depended on ROS production, and ROS scavengers reversed thioridazine-mediated c-FLIP(L) and Mcl-1 downregulation (Figure 6b) . However, the mechanism by which thioridazine modulates proteasome activity is unclear. We examined the effect of thioridazine on the protein expression of two critical proteasome subunits: PSMA5 and PSMD4/S5a. 23 However, thioridazine did not alter either protein (Figure 4d) . Therefore, the mechanism by which thioridazine modulates proteasome activity requires further evaluation.
Taken together, our results suggest that thioridazine sensitizes cancer cells, but not normal cells, to TRAILmediated apoptosis via the ROS-mediated inhibition of Akt signaling and downregulation of c-FLIP(L) and Mcl-1 expression at the post-translational levels. Therefore, the antipsychotic agent thioridazine may potentially be used to overcome TRAIL resistance in cancer cells. Western blot analysis. For the western blotting experiments, the cells were washed with cold phosphate-buffered saline (PBS) and lysed on ice in modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM Na 3 VO 4 , and 1 mM NaF) containing protease inhibitors (100 mM phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, 10 mg/ml pepstatin, and 2 mM EDTA). The lysates were centrifuged at 10 000 Â g for 10 min at 4 1C, and the supernatant fractions were collected. The proteins were separated by SDS-PAGE electrophoresis and transferred to Immobilon-P membranes (Millipore Corporation, Billerica, MA, USA). The specific proteins were detected using an enhanced chemiluminescence western blotting kit according to the manufacturer's instructions.
Flow cytometry analysis. For flow cytometry, the cells were resuspended in 100 ml of PBS, and 200 ml of 95% ethanol was added while the cells were being vortexed. The cells were then incubated at 4 1C for 1 h, washed with PBS, resuspended in 250 ml of 1.12% sodium citrate buffer (pH 8.4) with 12.5 mg of RNase, and incubated for an additional 30 min at 37 1C. The cellular DNA was then stained by adding 250 ml of a propidium iodide solution (50 mg/ml) to the cells for 30 min at room temperature. The stained cells were analyzed by fluorescenceactivated cell sorting on a FACScan flow cytometer (Becton Dickinson and Co., Franklin Lakes, NY, USA) to determine the relative DNA content, which was based on the red fluorescence intensity.
0 -Diamidino-2-phenylindole staining for nuclei condensation and fragmentation. To examine cellular nuclei, the cells were fixed with 1% paraformaldehyde on glass slides for 30 min at room temperature. After fixation, the cells were washed with PBS and a 300 nM 4 0 ,6 0 -diamidino-2-phenylindole solution (Roche, Mannheim, Germany) was added to the fixed cells for 5 min. After the nuclei were stained, the cells were examined by fluorescence microscopy.
The DNA fragmentation assay. The cell death detection ELISA plus kit (Boerhringer Mannheim; Indianapolis, IN, USA) was used to determine the level of apoptosis by detecting fragmented DNA within the nuclei of thioridazine-treated cells, TRAIL-treated cells, or cells that had been treated with a combination of thioridazine and TRAIL. Briefly, each culture plate was centrifuged for 10 min at 200 Â g, the supernatant was removed, and the cell pellet was lysed for 30 min. The plate was then centrifuged again at 200 Â g for 10 min, and the supernatant that contained the cytoplasmic histone-associated DNA fragments was collected and incubated with an immobilized anti-histone antibody. The reaction products were incubated with a peroxidase substrate for 5 min and measured by spectrophotometry at 405 nm and 490 nm (reference wavelength) with a microplate reader. The signals in the wells containing the substrate alone were subtracted as the background.
Asp-Glu-Val-Asp-ase (DEVDase) activity assay. To evaluate DEVDase activity, cell lysates were prepared after their respective treatments with TRAIL in the presence or absence of thioridazine. Assays were performed in 96-well microtiter plates by incubating 20 mg of cell lysates in 100 ml of reaction buffer (1% NP-40, 20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 10% glycerol) Mcl-1 and c-FLIP(L) constructs and stable cell. The human Mcl-1 and c-FLIP(L) expression vectors were constructed, as described previously. 38, 39 The Caki cells were transfected in a stable manner with the pFLAG-CMV-4/Mcl-1 or pcDNA 3.1-c-FLIP(L) plasmid using LipofectAMINE (Invitrogen, Carlsbad, CA, USA), as prescribed by the manufacturer. After 48 h of incubation, transfected cells were selected in cell culture medium containing 700 mg/ml G418 (Invitrogen). After 2 or 3 weeks, single independent clones were randomly isolated, and each individual clone was plated separately. After clonal expansion, cells from each independent clone were tested for Mcl-1 or c-FLIP(L) expression by immunoblotting and were used in this study.
Proteasome activity assay. The chymotryptic proteasome activities were measured with Suc-LLVY-AMC (chymotryptic substrate, Biomol International, Plymouth Meeting, PA, USA). The cells were collected, washed with PBS, and lysed. A mixture containing 1 mg protein of the cell lysate in 100 mM Tris-HCl (pH 8.0), 10 mM MgCl 2 , and 2 mM ATP was incubated at 37 1C for 30 min with 50 mM Suc-LLVY-AMC. The enzyme activity was measured with a fluorometric plate reader at an excitation wavelength of 380 nm and an emission wavelength of 440 nm. The measurement of proteasome activity within cells was determined using ZsGreen (proteasome sensor vector)-transfected stable Caki cell lines (BD Biosciences). ZsGreen fused with a destabilization sequence subjected to rapid ubiquitination and degradation by proteasome in mouse ornithine decarboxylase. Fluorescence was detected using a fluorescence microscope and FACS Cantot (BD Biosciences).
Measurement of ROS.
The intracellular accumulation of ROS was determined using the fluorescent probes 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (H 2 DCFDA). H 2 DCFDA is commonly used to measure ROS generation. 40 Caki cells were pretreated with 5 mM NAC, 2 mM GEE, and 200 mM trolox for 30 min, Statistical analysis. The data were analyzed using a one-way ANOVA and post-hoc comparisons (Student-Newman-Keuls) using the Statistical Package for Social Sciences 8.0 software (SPSS Inc., Chicago, IL, USA).
